ScandiDos AB (SE:SDOS)

:SDOS

SDOS

ScandiDos AB

RESEARCH TOOLSreports

Want to see SE:SDOS full AI Analyst Report?

ScandiDos AB (SDOS) Price & Analysis

0 Followers

SDOS Stock Chart & Stats

kr1.15

kr0.01(0.67%)

At close: Mar 06 4:00 PM EST

kr1.15

kr0.01(0.67%)

Day’s Range― - ―

52-Week Rangekr0.90 - kr1.50

Previous CloseN/A

Volume16.76K

Average Volume (3M)69.69K

Market Cap

kr57.58M

Enterprise Valuekr51.73M

Total Cash (Recent Filing)kr5.85M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.39

Next Earnings

Jun 17, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.07

Shares Outstanding57,011,086

10 Day Avg. Volume66,689

30 Day Avg. Volume69,692

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)1.28

Price to Sales (P/S)0.95

P/FCF Ratio-21.18

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetScandiDos' essentially debt-free balance sheet provides durable financial flexibility. With minimal leverage the company can prioritize R&D, absorb working-capital swings and support clinical sales cycles without near-term refinancing risk, reducing solvency pressure over 2–6 months.

Narrowing Losses / Improving MarginsMaterial reduction in net losses signals improving cost control or a better product mix. If this trend persists, it lowers future financing needs, supports pathway to sustainable profitability and strengthens operational resilience important for a small med‑tech business over the medium term.

Niche QA Product With Recurring Revenue PotentialScandiDos operates in specialized radiotherapy QA with hardware, software licenses and service contracts. The mix creates recurring revenue potential and stickiness with hospitals, supporting more predictable cash flows and higher switching costs versus commodity device sellers over multiple quarters.

Bears Say

Revenue DeclineTrailing revenue contraction undermines scale economics for a small med‑tech vendor. Continued top-line weakness limits margin expansion, squeezes investment capacity for commercialization, and raises execution risk for regaining growth in the next several quarters.

Negative Cash Flow / Ongoing Cash BurnPersistent negative operating and free cash flow reduces runway and forces reliance on external funding. For a company with long clinical sales cycles, this constrains R&D and commercial investment pace and increases financing and dilution risk over a 2–6 month horizon.

Persistent UnprofitabilityDespite improvement, EBIT and net income remain negative, meaning the business has not yet converted revenue into sustainable returns. Continued unprofitability limits internal capital generation and heightens dependence on external financing until consistent positive earnings are achieved.

SDOS FAQ

What was ScandiDos AB’s price range in the past 12 months?

ScandiDos AB lowest stock price was kr0.90 and its highest was kr1.50 in the past 12 months.

What is ScandiDos AB’s market cap?

ScandiDos AB’s market cap is kr57.58M.

When is ScandiDos AB’s upcoming earnings report date?

ScandiDos AB’s upcoming earnings report date is Jun 17, 2026 which is in 24 days.

How were ScandiDos AB’s earnings last quarter?

ScandiDos AB released its earnings results on Mar 18, 2026. The company reported -kr0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.03.

Is ScandiDos AB overvalued?

According to Wall Street analysts ScandiDos AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ScandiDos AB pay dividends?

ScandiDos AB does not currently pay dividends.

What is ScandiDos AB’s EPS estimate?

ScandiDos AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ScandiDos AB have?

ScandiDos AB has 57,011,086 shares outstanding.

What happened to ScandiDos AB’s price movement after its last earnings report?

ScandiDos AB reported an EPS of -kr0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.99%.

Which hedge fund is a major shareholder of ScandiDos AB?

Currently, no hedge funds are holding shares in SE:SDOS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ScandiDos AB

ScandiDos AB (publ) provides measurement systems and software designed for the QA and validation requirements of the new treatments implemented in clinics worldwide. The company offers Delta4 Family solution for pre treatment and at treatment dose verification covering various treatment technologies, such as VMAT, IMRT, SBRT, 4D-RT, and TomoTherapy; Delta4 Discover, a transmission detector that provides confidence and patient safety based on real time measurements; and Delta4 Phantom+, a system that offers accurate and verification of IMRT, VMAT, and TomoTherapy plans. It also provides HexaMotion, a motion management solution; Delta4DVH Anatomy, a software that verifies and analyzes the dose delivered in the patient anatomy; and Delta4 Machine QA, a software to perform QA with respect to rotation, start-up behavior, and dynamic beam modulation. The company was founded in 2005 and is headquartered in Uppsala, Sweden.